Biodesix (BDSX) Panoramica del titolo
Biodesix, Inc. opera come azienda di soluzioni diagnostiche. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 1/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
BDSX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Biodesix, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$21.85 |
| Massimo di 52 settimane | US$24.92 |
| Minimo di 52 settimane | US$5.26 |
| Beta | 0.52 |
| Variazione di 1 mese | 41.33% |
| Variazione a 3 mesi | 50.38% |
| Variazione di 1 anno | 296.12% |
| Variazione a 3 anni | -6.22% |
| Variazione a 5 anni | -91.16% |
| Variazione dall'IPO | -91.47% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Jun 25
BDSX: Durable Gross Margins And EBITDA Breakeven Path Will Support Higher Confidence
The analyst price target for Biodesix has been revised modestly higher from about $30.50 to roughly $30.83, with analysts pointing to expectations for durable top line growth, strong gross margins, and a path toward adjusted EBITDA breakeven as key supports for the updated view. Analyst Commentary Recent research on Biodesix highlights a generally constructive stance, with price targets clustered in the high $20s to low $30s and commentary focused on growth, margins, and the path to adjusted EBITDA breakeven.
Aggiornamento della narrazione • Jun 11
BDSX: Larger Lung Nodule Study And 2026 Guidance Will Support Upside
Analysts have raised their price target on Biodesix by $2 to $22, citing updated expectations around fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Biodesix raised its consolidated earnings guidance for fiscal 2026, now expecting total revenue of US$108–114 million versus prior guidance of US$106–112 million, with the midpoint implying approximately 25% growth over 2025 compared with the earlier midpoint of 23% growth.Aggiornamento della narrazione • May 28
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Higher Confidence
Analysts nudged their Biodesix price target higher by $0.50 to $30.50, citing Street research that highlights slightly adjusted growth and discount rate assumptions, better profit margin expectations, and recent upgrades tied to revenue guidance and an improved balance sheet. Analyst Commentary Recent Street research gives you a mixed but constructive picture of how analysts are thinking about Biodesix, with some focusing on execution and balance sheet progress, and others more cautious around what is already reflected in the valuation.
Aggiornamento della narrazione • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.Recent updates
Aggiornamento della narrazione • Jun 25
BDSX: Durable Gross Margins And EBITDA Breakeven Path Will Support Higher Confidence
The analyst price target for Biodesix has been revised modestly higher from about $30.50 to roughly $30.83, with analysts pointing to expectations for durable top line growth, strong gross margins, and a path toward adjusted EBITDA breakeven as key supports for the updated view. Analyst Commentary Recent research on Biodesix highlights a generally constructive stance, with price targets clustered in the high $20s to low $30s and commentary focused on growth, margins, and the path to adjusted EBITDA breakeven.Aggiornamento della narrazione • Jun 11
BDSX: Larger Lung Nodule Study And 2026 Guidance Will Support Upside
Analysts have raised their price target on Biodesix by $2 to $22, citing updated expectations around fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Biodesix raised its consolidated earnings guidance for fiscal 2026, now expecting total revenue of US$108–114 million versus prior guidance of US$106–112 million, with the midpoint implying approximately 25% growth over 2025 compared with the earlier midpoint of 23% growth.Aggiornamento della narrazione • May 28
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Higher Confidence
Analysts nudged their Biodesix price target higher by $0.50 to $30.50, citing Street research that highlights slightly adjusted growth and discount rate assumptions, better profit margin expectations, and recent upgrades tied to revenue guidance and an improved balance sheet. Analyst Commentary Recent Street research gives you a mixed but constructive picture of how analysts are thinking about Biodesix, with some focusing on execution and balance sheet progress, and others more cautious around what is already reflected in the valuation.Aggiornamento della narrazione • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.Aggiornamento della narrazione • Apr 16
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating
Analysts have nudged their price target on Biodesix higher to $30.00 from $30, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and three consecutive quarters of execution above target as reasons for a more constructive view. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to an Outperform rating as a signal that recent execution and guidance support a higher valuation framework than before.Aggiornamento della narrazione • Apr 01
BDSX: Strong Guidance And Healthier Balance Sheet Will Support 2026 Momentum
Analysts have raised their price target on Biodesix from $30.00 to $56.14, citing 2026 revenue guidance that is 3% above prior expectations and a "significantly improved" balance sheet, with execution running above target for three consecutive quarters. Analyst Commentary Bullish Takeaways Bullish analysts point to the 2026 revenue guidance coming in 3% above prior expectations as support for a higher valuation range, given that it directly feeds into forward revenue estimates and P/S assumptions.Aggiornamento della narrazione • Mar 18
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upside
Analysts have maintained their price target on Biodesix, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and what they see as three consecutive quarters of above target execution heading into 2026. Analyst Commentary The latest upgrade frames Biodesix as entering 2026 with momentum, supported by revenue guidance that sits 3% ahead of expectations and an improved balance sheet.Aggiornamento della narrazione • Mar 04
BDSX: Improved Balance Sheet And Guidance Will Support Momentum Into 2026
Analysts have reduced their price target on Biodesix from $35 to $30, citing updated fair value assumptions along with views that recent revenue guidance, improving margins, and a lower discount rate better reflect the company’s execution and balance sheet strength. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgrade to an Outperform rating as a sign that recent execution and guidance are more in line with what they view as fair value.Aggiornamento della narrazione • Feb 18
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have revised their price target on Biodesix to $40.00 from $40, reflecting updated views on discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Biodesix raised its revenue guidance for the fiscal year ending December 31, 2025, estimating total revenue of $88.5 million, above the previously increased range of $84 million to $86 million (company guidance).Aggiornamento della narrazione • Feb 02
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have adjusted their price target on Biodesix to US$40.00 from US$40, citing updated assumptions around discount rates, revenue growth, profit margin, and future P/E that collectively refine, rather than overhaul, their previous view. What's in the News Biodesix issued new earnings guidance for the fourth quarter ended December 31, 2025, estimating total revenue of US$28.8 million for the period (Key Developments).Aggiornamento della narrazione • Jan 19
BDSX: Expanded Diagnostics Partnership Will Drive Revenue Upside In 2025
Analysts have increased their price target on Biodesix to reflect updated views on revenue growth potential and a slightly lower discount rate, while also adjusting expected profit margins and future P/E assumptions to align with their latest models. What's in the News Biodesix issued earnings guidance for the fourth quarter of 2025, estimating total revenue of $28.8 million for the period (Corporate guidance).Articolo di analisi • Jan 14
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump
Despite an already strong run, Biodesix, Inc. ( NASDAQ:BDSX ) shares have been powering on, with a gain of 26% in the...Aggiornamento della narrazione • Jan 05
BDSX: Expanded Diagnostics Partnership And ESR1 Assay Rollout Will Drive Upside
Analysts have lifted their price target on Biodesix to US$20.00 from US$1.50, citing adjusted assumptions around revenue growth, profit margin, discount rate, and a lower future P/E multiple as the key drivers of this revised view. What's in the News Biodesix raised its fiscal 2025 revenue guidance and now expects total revenue between US$84 million and US$86 million for the year (Key Developments).Aggiornamento della narrazione • Dec 14
BDSX: Reverse Split And ATM Access Will Support Path To Profitability
Analysts have significantly lifted their price target on Biodesix from $2.00 to $40.00, citing updated models following the 20 for 1 reverse split, a reduced share count, and the company’s ability to utilize its at the market facility to support operations through an expected path to cash flow breakeven and profitability. Analyst Commentary Bullish analysts interpret the new price target framework as a constructive signal for Biodesix, emphasizing that the reset reflects mechanical impacts from the 20 for 1 reverse split rather than a fundamental deterioration in the business outlook.Articolo di analisi • Nov 29
Biodesix, Inc.'s (NASDAQ:BDSX) Shares Leap 27% Yet They're Still Not Telling The Full Story
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...Articolo di analisi • Nov 05
US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results
Biodesix, Inc. ( NASDAQ:BDSX ) just released its latest quarterly results and things are looking bullish. Revenues and...Articolo di analisi • Sep 18
It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 27% over the previous 30 days, handing back...Aggiornamento della narrazione • Sep 16
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00. What's in the News Biodesix announced a 1-for-20 stock split.Articolo di analisi • Jul 29
The Market Lifts Biodesix, Inc. (NASDAQ:BDSX) Shares 67% But It Can Do More
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 67% in the...Articolo di analisi • Jun 14
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 30% in the...Articolo di analisi • May 15
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers
The latest analyst coverage could presage a bad day for Biodesix, Inc. ( NASDAQ:BDSX ), with the analysts making...Articolo di analisi • May 14
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year
Key Insights Biodesix's Annual General Meeting to take place on 20th of May Salary of US$588.9k is part of CEO Scott...Articolo di analisi • Apr 19
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 33% in the last...
Nuova narrazione • Apr 03
Sales Force Expansion And CLARIFY Study Will Boost Test Adoption
Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins.Articolo di analisi • Mar 05
It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 30% in the last...Articolo di analisi • Jan 19
The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Articolo di analisi • Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 26% in the last...Articolo di analisi • Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...Articolo di analisi • Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 25% over the previous 30 days, handing back...Articolo di analisi • Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...Articolo di analisi • Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 28% in the last...Rendimenti per gli azionisti
| BDSX | US Healthcare | US Mercato | |
|---|---|---|---|
| 7D | -8.2% | 1.8% | 0.8% |
| 1Y | 296.1% | 28.5% | 20.2% |
Ritorno vs Industria: BDSX ha superato il US Healthcare che ha restituito 28.5 % nell'ultimo anno.
Rendimento vs Mercato: BDSX ha superato il mercato US che ha restituito 20.2 % nell'ultimo anno.
Volatilità dei prezzi
| BDSX volatility | |
|---|---|
| BDSX Average Weekly Movement | 15.4% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di BDSX è stato volatile rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 15% ) di BDSX è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2005 | 334 | Scott Hutton | www.biodesix.com |
Biodesix, Inc. opera come società di soluzioni diagnostiche. L'azienda offre test polmonari su base ematica, tra cui i mercati dei test Nodify XL2 e Nodify CDT come test di valutazione del rischio dei noduli polmonari Nodify, per valutare il rischio di cancro ai polmoni e aiutare a identificare il percorso terapeutico appropriato, nonché aiutare i medici a riclassificare il rischio di malignità nei pazienti con noduli polmonari sospetti. L'azienda fornisce anche i mercati dei test GeneStrat ddPCR, GeneStrat NGS e VeriStrat, nell'ambito della strategia di analisi IQLung, che vengono utilizzati nella diagnosi del cancro al polmone per misurare la presenza di mutazioni nel tumore e lo stato del sistema immunitario del paziente per orientare le decisioni terapeutiche.
Biodesix, Inc. Riepilogo dei fondamenti
| BDSX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$227.72m |
| Utili (TTM) | -US$31.96m |
| Ricavi(TTM) | US$96.10m |
2.4x
Rapporto P/S-7.1x
Rapporto P/EBDSX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| BDSX Conto economico (TTM) | |
|---|---|
| Ricavi | US$96.10m |
| Costo del fatturato | US$17.62m |
| Profitto lordo | US$78.48m |
| Altre spese | US$110.43m |
| Utili | -US$31.96m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -3.09 |
| Margine lordo | 81.66% |
| Margine di profitto netto | -33.26% |
| Rapporto debito/patrimonio netto | 509.1% |
Come si è comportato BDSX nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/06 15:29 |
| Prezzo dell'azione a fine giornata | 2026/07/06 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Biodesix, Inc. è coperta da 10 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| William Bonello | Craig-Hallum Capital Group LLC |